WO2017192671A1 - Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same - Google Patents

Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same Download PDF

Info

Publication number
WO2017192671A1
WO2017192671A1 PCT/US2017/030764 US2017030764W WO2017192671A1 WO 2017192671 A1 WO2017192671 A1 WO 2017192671A1 US 2017030764 W US2017030764 W US 2017030764W WO 2017192671 A1 WO2017192671 A1 WO 2017192671A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
vaccine composition
yeast
hmgb
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/030764
Other languages
English (en)
French (fr)
Inventor
Billy Hargis
Leona Nicole CALHOUN
Luc Berghman
Lisa Bielke
Olivia B. FAULKNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Original Assignee
Texas A&M University System
University of Arkansas at Fayetteville
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2018558201A priority Critical patent/JP7467027B2/ja
Priority to AU2017260323A priority patent/AU2017260323B2/en
Priority to KR1020187034980A priority patent/KR20190015712A/ko
Priority to KR1020237015693A priority patent/KR102767638B1/ko
Priority to MX2018013331A priority patent/MX2018013331A/es
Priority to EP17793221.7A priority patent/EP3452069A4/en
Priority to CA3023144A priority patent/CA3023144A1/en
Priority to SG11201809686SA priority patent/SG11201809686SA/en
Application filed by Texas A&M University System, University of Arkansas at Fayetteville, University of Arkansas at Little Rock filed Critical Texas A&M University System
Priority to BR112018072592-7A priority patent/BR112018072592A2/pt
Publication of WO2017192671A1 publication Critical patent/WO2017192671A1/en
Anticipated expiration legal-status Critical
Priority to JP2022007727A priority patent/JP2022040389A/ja
Priority to AU2023255055A priority patent/AU2023255055A1/en
Priority to JP2023209806A priority patent/JP2024023648A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • HMGB 1 polypeptides and functional fragments or homolog s thereof include polypeptides identical to, or at least 99% identical, at least 98% identical, at least 95% identical, at least 90% identical, at least 85% identical, or at least 80% identical to the HMGB 1 polypeptides of the chicken HMGB 1 sequence or HMGB 1 box al, HMGB 1 box a2, HMGB 1 box bl, HMGB 1 box b2, HMGB 1 RAGE binding domain, or HMGB 1 proinflammatory cytokine activity, respectively.
  • the CD40 ligand may be a CD40 agonistic antibody or portion thereof.
  • CD40 agonistic antibodies are disclosed at least in International Application No. WO2015/187969.
  • CD40 antibodies and agonisitic CD40 antibodies are also commercially available for several species, in particular mouse and human.
  • An antibody is agonistic for CD40 if it is capable of inducing signaling within the target cell expressing CD40. The signalling via CD40 results in increased expression of CD40 and TNF receptors on the surface of the antigen- presenting cells and induces production of reactive oxygen species and nitric oxide, and B cell activation leading to isotype switching.
  • Polynucleotides encoding the antigenic polypeptide or immunostimulatory polypeptides may be inserted into the yeast of the vaccine composition and expressed to generate the antigenic polypeptide and the immunostimulatory polypeptide.
  • the polynucleotides may be inserted into the chromosome of the vaccine composition or encoded on plasmids or other extrachromosomal DNA such as on a YAC (yeast artificial chromosome).
  • YAC yeast artificial chromosome
  • polynucleotides encoding the antigenic polypeptide and/or the immunostimulatory polypeptide may be expressed independently or are inserted into a yeast vaccine polynucleotide that is expressed.
  • Heterologous polynucleotides can also be obtained from pathogenic bacteria, e.g., genes encoding bacterial proteins such as toxins, and outer membrane proteins. Further, heterologous polynucleotides from parasites, such as Eimeria are attractive candidates for use in a yeast vectored vaccine composition.
  • HMGB 1 has engineered Pichia pastoris for cell surface expression of HMGB 1 using a plasmid integrated system to chromosomally insert the HMGB 1 protein into Pichia pastoris increasing the immune response to the vaccine cargo.
  • Pichia pastoris yields 10- to 100-fold higher protein expression than Saccharomyces cerevisiae.
  • HMGB 1 sends a danger signal to the immune system triggering the RAGE response.
  • the phagocytosis assay described above shows that HMGB l is a potent immune stimulatory molecule that can increase uptake of the carrier system, for example, Salmonella Enteriditis, into murine macrophages.
  • the Pichia pastoris-HMGB 1 positive clones #3, 4, and 6 were inactivated using 0.3% glutaraldehyde in sterile water and mixed 1:2 in mannosylated chitosan adjuvant. See WO 2014/070709 which is incorporated herein by reference in its entirety.
  • Pichia pastoris X-33 wild type was obtained from Invitrogen (Carlsbad, CA, USA) as part of the Easy SelectTM Pichia Expression Kit.
  • TOP10 electrocompetent E. coli (Invitrogen) was used for all necessary plasmid propagation during vaccine construction. Following transformations with plasmid DNA, E. coli was propagated at 37°C using either LB medium supplemented with 100 ⁇ g/mL Ampicillin, or low salt LB medium containing 50 ⁇ g/mL Zeocin.
  • the MCA (0.5%) plus Pichia construct (1x10 cells) was delivered in 0.25 mL for both the prime and the boost by oral gavage.
  • the final concentration of MCA in the drinking water was 0.004% and the final concentration of the Pichia was 2.3 x 10 6 cells/mL of drinking water and this was used for both prime and boost administration.
  • the lesion data were analyzed using a PROC MIXED ANOVA model in SAS, the assumption was made that the difference in severity between a score of 0 and 1 was similar to the difference in severity between a score of 1 and 2, and so on. Under this assumption, score means may be analyzed for the PROC MIXED ANOVA analysis. Lesion scores range from 0 to 4 as described by Johnson and Reid (1970). Tests of random and fixed effects were performed. The differences of means were calculated to determine any significant differences between lesion scores among treatment groups. The data was determined to have a Poisson distribution and a Tukey Kramer test was used to determine whether there were any statistically significant differences between treatment groups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
PCT/US2017/030764 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same Ceased WO2017192671A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA3023144A CA3023144A1 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
KR1020187034980A KR20190015712A (ko) 2016-05-03 2017-05-03 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
KR1020237015693A KR102767638B1 (ko) 2016-05-03 2017-05-03 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
MX2018013331A MX2018013331A (es) 2016-05-03 2017-05-03 Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso.
EP17793221.7A EP3452069A4 (en) 2016-05-03 2017-05-03 Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
SG11201809686SA SG11201809686SA (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
BR112018072592-7A BR112018072592A2 (pt) 2016-05-03 2017-05-03 vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
JP2018558201A JP7467027B2 (ja) 2016-05-03 2017-05-03 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法
AU2017260323A AU2017260323B2 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
JP2022007727A JP2022040389A (ja) 2016-05-03 2022-01-21 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法
AU2023255055A AU2023255055A1 (en) 2016-05-03 2023-10-30 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
JP2023209806A JP2024023648A (ja) 2016-05-03 2023-12-13 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331044P 2016-05-03 2016-05-03
US62/331,044 2016-05-03

Publications (1)

Publication Number Publication Date
WO2017192671A1 true WO2017192671A1 (en) 2017-11-09

Family

ID=60203263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/030764 Ceased WO2017192671A1 (en) 2016-05-03 2017-05-03 Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Country Status (12)

Country Link
US (2) US10682398B2 (enExample)
EP (1) EP3452069A4 (enExample)
JP (3) JP7467027B2 (enExample)
KR (2) KR20190015712A (enExample)
AR (1) AR108688A1 (enExample)
AU (2) AU2017260323B2 (enExample)
BR (1) BR112018072592A2 (enExample)
CA (1) CA3023144A1 (enExample)
MX (1) MX2018013331A (enExample)
SG (1) SG11201809686SA (enExample)
TW (2) TWI758288B (enExample)
WO (1) WO2017192671A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2629797B1 (en) 2010-10-19 2018-05-23 The Regents of the University of Colorado, A Body Corporate Peptides for modulating t-cell activity and uses thereof
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12618074B2 (en) 2019-04-11 2026-05-05 The Board Of Trustees Of The University Of Arkansas CD40 specific DNA aptamers as vaccine adjuvants
EP3996731A4 (en) * 2019-07-12 2023-07-12 Op-T Llc PEPTIDES AND METHODS OF TREATMENT OF DISEASES
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
JP2025127116A (ja) 2024-02-20 2025-09-01 セイコーエプソン株式会社 液体吐出装置及び液体吐出装置の制御方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102079A1 (en) * 2006-10-27 2008-05-01 Dow Agrosciences Llc Poultry Vaccine, for Necrotic Enteritis, Comprising a Mutated Clostridium Perfringens Alpha Toxin Antigen, and Methods of Producing the Vaccine
US20160038581A1 (en) * 2013-03-15 2016-02-11 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK55593A3 (en) 1991-03-05 1993-10-06 Wellcome Found Expresion of recombinant proteins in attenuated bacteria
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
EP0659086B1 (en) 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
PT812206E (pt) 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
NZ311335A (en) 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
EP1059932A1 (en) 1997-12-19 2000-12-20 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
ATE403728T1 (de) 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
IL144952A0 (en) 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US7118751B1 (en) 1999-10-14 2006-10-10 Trubion Pharmaceuticals, Inc. DNA vaccines encoding antigen linked to a domain that binds CD40
DK1112747T3 (da) 1999-12-28 2004-10-25 Akzo Nobel Nv Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
EP1255560B1 (en) 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40 ligand adjuvant for respiratory syncytial virus vaccine
BR0109322A (pt) 2000-03-17 2002-12-10 Upjohn Co Materiais e métodos de vacina de salmonella
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
WO2002000232A2 (en) 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
BR0209689A (pt) 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
ATE395602T1 (de) 2001-12-19 2008-05-15 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
AU2002359780B2 (en) 2001-12-21 2009-08-13 Immunex Corporation Recombinant polypeptides
ATE421249T1 (de) 2002-02-13 2009-02-15 Immunology Lab Inc Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
EP2380440B1 (en) 2002-04-15 2016-03-09 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
JP2006510619A (ja) 2002-11-20 2006-03-30 クリティカル セラピューティクス，インコーポレイテッド 抗炎症剤としてのｈｍｇｂ断片の使用
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
WO2004046338A2 (en) 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Use of hmgb polypeptides for increasing immune responses
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
ES2358804T3 (es) 2003-11-21 2011-05-13 Ace Biosciences A/S Polipéptidos de campylobacter jejuni ubicados en superficie.
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
WO2006069610A2 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
PT1949913E (pt) 2005-10-07 2010-08-24 Proyecto Biomedicina Cima Sl Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
AU2006311752A1 (en) 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
AU2007248559A1 (en) * 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
CA2659267C (en) 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
AU2008275513A1 (en) 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
BRPI0916349A2 (pt) 2008-09-11 2019-09-24 Pasteur Institut monitoramento e inibição da infecção pelo vírus da imunodeficiência humana através da modulação do desencadeamento dependete de hmgb1 da replicação e persistência do hiv-1
US8163281B2 (en) 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
DK2365332T3 (da) 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EA031234B1 (ru) 2012-10-29 2018-12-28 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Вакцина с адъювантом на основе маннозилированного хитозана
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
SG11201609965XA (en) 2014-06-05 2016-12-29 Univ Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102079A1 (en) * 2006-10-27 2008-05-01 Dow Agrosciences Llc Poultry Vaccine, for Necrotic Enteritis, Comprising a Mutated Clostridium Perfringens Alpha Toxin Antigen, and Methods of Producing the Vaccine
US20160038581A1 (en) * 2013-03-15 2016-02-11 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Also Published As

Publication number Publication date
AU2017260323B2 (en) 2023-11-16
KR20190015712A (ko) 2019-02-14
AU2017260323A1 (en) 2018-12-20
JP7467027B2 (ja) 2024-04-15
US20170319671A1 (en) 2017-11-09
TWI843057B (zh) 2024-05-21
KR102767638B1 (ko) 2025-02-20
JP2022040389A (ja) 2022-03-10
KR20230070521A (ko) 2023-05-23
AU2023255055A1 (en) 2023-11-16
TW202224701A (zh) 2022-07-01
US20200297825A1 (en) 2020-09-24
SG11201809686SA (en) 2018-11-29
US11382962B2 (en) 2022-07-12
MX2018013331A (es) 2019-06-10
JP2019514971A (ja) 2019-06-06
EP3452069A4 (en) 2020-02-12
BR112018072592A2 (pt) 2019-04-16
TW201803590A (zh) 2018-02-01
EP3452069A1 (en) 2019-03-13
US10682398B2 (en) 2020-06-16
JP2024023648A (ja) 2024-02-21
CA3023144A1 (en) 2017-11-09
TWI758288B (zh) 2022-03-21
AR108688A1 (es) 2018-09-19

Similar Documents

Publication Publication Date Title
US11382962B2 (en) Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11013792B2 (en) Compositions and methods of enhancing immune responses to enteric pathogens
US11364290B2 (en) Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
HK1218880B (en) Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
NZ711761B2 (en) Compositions and methods of enhancing immune responses to enteric pathogens

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3023144

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018558201

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018072592

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17793221

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20187034980

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017793221

Country of ref document: EP

Effective date: 20181203

ENP Entry into the national phase

Ref document number: 2017260323

Country of ref document: AU

Date of ref document: 20170503

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112018072592

Country of ref document: BR

Free format text: COMO FORAM SOLICITADOS 2 SERVICOS (TRADUCAO DOS DOCUMENTOS APRESENTADOS NO DEPOSITO E MODIFICACAO DAS REIVINDICACOES APRESENTADAS NO DEPOSITO) ATRAVES DA PETICAO 870180152798 E, DE ACORDO COM A RESOLUCAO NO189/2017 DEVEM SER PAGAS RETRIBUICOES ESPECIFICAS PARA CADA UM DOS SERVICOS SOLICITADOS, SE FAZ NECESSARIA A COMPLEMENTACAO DO PAGAMENTO, UM PARA CADA SERVICO.

ENP Entry into the national phase

Ref document number: 112018072592

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181101

WWW Wipo information: withdrawn in national office

Ref document number: 748934

Country of ref document: NZ